OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

On July 29, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915 (Press release, OncoSec Medical, JUL 29, 2019, View Source [SID1234537846]). The allowed patent application covers methods of treating a patient having treatment-refractory, cutaneous or subcutaneous, cancerous tumors, that involve injecting the tumor with a plasmid coding for an immunostimulatory cytokine (e.g. IL-12), electroporating the tumor, and administering a checkpoint inhibitor to the patient. This allowance is significant because it is not specific to which cytokine or checkpoint inhibitor can be used to treat a patient, nor is it limited to a particular type of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The claims granted by the USPTO provide OncoSec with broad-based protection on the very valuable combination of intratumoral cytokines, electroporation and checkpoint inhibitor therapy. We continue to fortify the patent portfolio around our technology, which employs electroporation and local cytokine delivery and continues to demonstrate impressive systemic tumor responses, particularly when combined with checkpoint inhibitors," said Daniel J. O’Connor, President and Chief Executive Officer of OncoSec.

OncoSec maintains a robust intellectual property strategy to protect its leadership position in the development of cytokine-based intratumoral immunotherapies and now owns or has rights to 88 granted patents and 60 pending patent applications worldwide.